Jasmin Quandt

Jasmin Quandt

Auto-generated profile, based on publicly available information

Jasmin Quandt

BioNTech, Mainz, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in Nature
Verified
Journal Article
Open access
PDF file
USUgur Sahin
Ugur Sahin
AMAlexander Muik
Alexander Muik
EDEvelyna Derhovanessian
Evelyna Derhovanessian
IVIsabel Vogler
Isabel Vogler
LKLena M. Kranz
Lena M. Kranz
ÖTÖzlem Türeci
Özlem Türeci
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T-cell responses after BNT162b1 vaccination from a second, non-randomized open-label phase 1/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 µg of BNT162b1 elicited robust CD4+ and CD8+ T-cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those in a COVID-19 human convalescent sample (HCS) panel. Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-fold (1 µg) to 3.5-fold (50 µg) those of the HCS panel. Immune sera broadly neutralised pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1) skewed T cell immune responses with RBD-specific CD8+ and CD4+ T-cell expansion. Interferon (IFN)γ was produced by a high fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.

27 May 2021 in Nature
Verified
Journal Article
Closed access
PDF file
USUgur Sahin
Ugur Sahin
AMAlexander Muik
Alexander Muik
IVIsabel Vogler
Isabel Vogler
EDEvelyna Derhovanessian
Evelyna Derhovanessian
LKLena M. Kranz
Lena M. Kranz
ÖTÖzlem Türeci
Özlem Türeci

30 September 2022 in Science Immunology
Verified
Journal Article
Open access
JQJasmin Quandt
Jasmin Quandt
AMAlexander Muik
Alexander Muik
NSNadine Salisch
Nadine Salisch
BLBonny Gaby Lui
Bonny Gaby Lui
SLSebastian Lutz
Sebastian Lutz
USUgur Sahin
Ugur Sahin
Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted in strong neutralizing activity against Omicron BA.1, BA.2, and previous SARS-CoV-2 VOCs but not against the Omicron sublineages BA.4 and BA.5. BA.1 breakthrough infection induced a robust recall response, primarily expanding memory B (B MEM ) cells against epitopes shared broadly among variants, rather than inducing BA.1-specific B cells. The vaccination-imprinted B MEM cell pool had sufficient plasticity to be remodeled by heterologous SARS-CoV-2 spike glycoprotein exposure. Whereas selective amplification of B MEM cells recognizing shared epitopes allows for effective neutralization of most variants that evade previously established immunity, susceptibility to escape by variants that acquire alterations at hitherto conserved sites may be heightened.

19 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
USUgur Sahin
Ugur Sahin
AMAlexander Muik
Alexander Muik
EDEvelyna Derhovanessian
Evelyna Derhovanessian
IVIsabel Vogler
Isabel Vogler
LKLena M. Kranz
Lena M. Kranz
ÖTÖzlem Türeci
Özlem Türeci

16 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
USUgur Sahin
Ugur Sahin
AMAlexander Muik
Alexander Muik
IVIsabel Vogler
Isabel Vogler
EDEvelyna Derhovanessian
Evelyna Derhovanessian
LKLena M. Kranz
Lena M. Kranz
ÖTÖzlem Türeci
Özlem Türeci

21 June 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
EMEssack Mitha
Essack Mitha
MBMezgebe Berhe
Mezgebe Berhe
JAJudith Aberg
Judith Aberg
CLChristopher J Lucasti
Christopher J Lucasti
FCFadi Chalhoub
Fadi Chalhoub
AGAlejandra Gurtman
Alejandra Gurtman
Background: People with human immunodeficiency virus (HIV) are at increased risk of severe COVID-19 and are recommended for priority vaccination. We investigated the safety and immunogenicity of a 2-dose regimen of the mRNA vaccine BNT162b2 in people with HIV (PWH) on antiretroviral therapy (ART). Methods: Safety, reactogenicity, and immunogenicity data were obtained from PWH on ART ≥16 years enrolled in the phase 1/2/3 BNT162-02 trial/C4591001 (NCT04368728) between September and November 2020, which randomized participants (1:1) to receive BNT162b2 or placebo. Immunogenicity was also investigated in a substudy of the open-label phase 1/2 BNT162-01 trial (NCT04380701) in PWH aged 18–85 years and age- and sex- matched HIV-negative controls enrolled February to March 2021. Results: In total, 201 PWH were included from the BNT162-02 trial. Higher rates of local and systemic reactions were reported during the 7 days following both doses by participants administered BNT162b2 versus participants administered placebo, most notably pain at injection site, fatigue, headache, and chills. Most reactions were mild to moderate in severity. No serious adverse events occurred up to 1 month post–dose 2. Spike protein–binding and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody responses were elicited in participants who received BNT162b2 and remained above prevaccination baseline levels through 6 months post–dose 2. In the BNT162-01 trial, all PWH (N = 15) seroconverted, with BNT162b2-induced SARS-CoV-2 neutralization titers and longitudinal T-cell responses similar to those observed in the HIV-negative cohort. Conclusions: Primary 2-dose vaccination with BNT162b2 in PWH was well tolerated and immunogenic with sustained responses up to 6 months, supporting vaccination in this priority population.